Log In
Print
BCIQ
Print
Print this Print this
 

Telomelysin (OBP-301)

  Manage Alerts
Collapse Summary General Information
Company Oncolys BioPharma Inc.
DescriptionOncolytic adenovirus
Molecular Target
Mechanism of ActionOncolytic virus
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationLiver cancer
Indication DetailsTreat locally advanced hepatocellular carcinoma (HCC)
Regulatory Designation

Partner

Medigen Biotechnology Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today